- Home
- ICU vs ACXP Comparison
ICU vs ACXP Comparison
Compare ICU & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- ACXP
- Stock Information
- Founded
- ICU 2018
- ACXP 2017
- Country
- ICU United States
- ACXP United States
- Employees
- ICU N/A
- ACXP N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- ACXP Health Care
- Exchange
- ICU Nasdaq
- ACXP Nasdaq
- Market Cap
- ICU 10.4M
- ACXP 9.0M
- IPO Year
- ICU N/A
- ACXP 2021
- Fundamental
- Price
- ICU $1.25
- ACXP $0.31
- Analyst Decision
- ICU
- ACXP Strong Buy
- Analyst Count
- ICU 0
- ACXP 1
- Target Price
- ICU N/A
- ACXP $12.00
- AVG Volume (30 Days)
- ICU 239.9K
- ACXP 186.5K
- Earning Date
- ICU 05-13-2025
- ACXP 05-13-2025
- Dividend Yield
- ICU N/A
- ACXP N/A
- EPS Growth
- ICU N/A
- ACXP N/A
- EPS
- ICU N/A
- ACXP N/A
- Revenue
- ICU $135,000.00
- ACXP N/A
- Revenue This Year
- ICU $648.15
- ACXP N/A
- Revenue Next Year
- ICU N/A
- ACXP N/A
- P/E Ratio
- ICU N/A
- ACXP N/A
- Revenue Growth
- ICU N/A
- ACXP N/A
- 52 Week Low
- ICU $1.21
- ACXP $0.30
- 52 Week High
- ICU $20.00
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- ICU 30.70
- ACXP 23.20
- Support Level
- ICU $1.21
- ACXP $0.30
- Resistance Level
- ICU $2.57
- ACXP $0.45
- Average True Range (ATR)
- ICU 0.21
- ACXP 0.02
- MACD
- ICU -0.09
- ACXP 0.00
- Stochastic Oscillator
- ICU 2.94
- ACXP 3.45
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.